Effect of somatostatin analogue octreotide in medulloblastoma in xenograft and cell culture study

Pediatric Hematology and Oncology

Volumn 26, Issue 5, 2009, Pages 363-374

  Hauser, Péter ^a   Hanzély, Zóltan ^b   Máthé, Domokos ^c   Szabó, Erika ^d   Barna, Gábor ^e   Sebestyén, Anna ^e   Jeney, András ^e   Schuler, Dezsõ ^a   Fekete, György ^a   Garami, Miklós ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

^c Department of Applied Radiopharmaceuticals   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cell culture; Daoy; Medulloblastoma; Octreotide; Somatostatin receptor; SSTR2A; Targeted therapy; Xenograft

Indexed keywords

CISPLATIN; ETOPOSIDE; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IC 50; LOW DRUG DOSE; MEDULLOBLASTOMA; MITOSIS; MONOLAYER CULTURE; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CISPLATIN; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; HUMANS; MEDULLOBLASTOMA; MICE; MICE, SCID; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68449102191     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010902973293     Document Type: Article

References (18)

1. Ferrari S, Dondi M, Fanti S, et al. Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm. 2003;18:847-851.
2. Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM. Somatostatin analogs in oncology: A look to the future. Chemotherapy. 2001;47 (Suppl 2):162-196.
3. Bohuslavizki KH, Brenner W, Braunsdorf WE, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun. 1996;17:302-310.
4. Guyotat J, Champier J, Jouvet A, et al. Differential expression of somatostatin receptors in ependymoma: Implications for diagnosis. Int J Cancer. 2001;95:144-151.
5. Guyotat J, Champier J, Pierre GS, et al. Differential expression of somatostatin receptors in medulloblastoma. J Neurooncol. 2001;51:93-103.
6. Fruhwald MC, Rickert CH, O'Dorisio MS, et al. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res. 2004;10:2997-3006.
7. Muller HL, Fruhwald MC, Scheubeck M, et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol. 1998;38:27-40.
8. Beutler D, Avoledo P, Reubi JC, et al. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer. 2005;103:869-873.
9. Glas M, Hennemann B, Hirschmann B, et al. Complete response after treatment with a somatostatin analogue in an adult patient with recurrent medulloblastoma. Acta Oncol. 2008;47:479-480.
10. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem. 1994;218:314-319.
11. Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. (99m)Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years' experience. Eur J Nucl Med Mol Imaging. 2006;33:1123-1133.
12. 99mTc/EDDA/ HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med. 2005;46:1561-1569.
13. Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61:1527-1532.
14. Vaidyanathan G, Boskovitz A, Shankar S, Zalutsky MR. Radioiodine and 211At-labeled guanidi-nomethyl halobenzoyl octreotate conjugates: Potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides. 2004;25:2087-2097.
15. Vaidyanathan G, Friedman HS, Affleck DJ, Schottelius M, Wester HJ, Zalutsky MR. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res. 2003;9:1868-1876.
16. Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol. 1997;26:1018-1025.
17. Li M, Zhang R, Li F, et al. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue. J Am Coll Surg. 2005;201:571-578.
18. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res. 2000;254:110-119.